Heron Therapeutics, Inc. (HRTX) News

Heron Therapeutics, Inc. (HRTX): $3.17

-0.31 (-8.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 393

in industry

Filter HRTX News Items

HRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HRTX News Highlights

  • HRTX's 30 day story count now stands at 5.
  • Over the past 22 days, the trend for HRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about HRTX are TWIN and NICE.

Latest HRTX News From Around the Web

Below are the latest news stories about Heron Therapeutics Inc that investors may wish to consider to help them evaluate HRTX as an investment opportunity.

Short Sellers Were Right About These 10 Stocks

In this article, we discuss the 10 stocks that short sellers were right about. If you want to skip our detailed analysis of these stocks, go directly to Short Sellers Were Right About These 5 Stocks. Short-sellers were the headliners of early 2021. A year later, these short-sellers are once again in the spotlight amid […]

Yahoo | February 24, 2022

Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the company will host a conference call and live webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights.

Yahoo | February 22, 2022

Strong week for Heron Therapeutics (NASDAQ:HRTX) shareholders doesn't alleviate pain of three-year loss

It's nice to see the Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price up 12% in a week. But that is small...

Yahoo | February 11, 2022

Twin Lakes Capital Management, LLC Buys Matterport Inc, DocuSign Inc, Teladoc Health Inc, Sells ...

Investment company Twin Lakes Capital Management, LLC (Current Portfolio) buys Matterport Inc, DocuSign Inc, Teladoc Health Inc, Blackrock Debt Strategies Fund Inc, Invesco Senior Income Trust, sells Alibaba Group Holding, Cango Inc, , Heron Therapeutics Inc, Air Products & Chemicals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Twin Lakes Capital Management, LLC.

Yahoo | February 7, 2022

Integral Health Asset Management, LLC Buys McKesson Corp, Centene Corp, Abbott Laboratories, ...

Investment company Integral Health Asset Management, LLC (Current Portfolio) buys McKesson Corp, Centene Corp, Abbott Laboratories, Biogen Inc, Amedisys Inc, sells Arena Pharmaceuticals Inc, Medtronic PLC, Hologic Inc, Zimmer Biomet Holdings Inc, Acadia Healthcare Co Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Integral Health Asset Management, LLC.

Yahoo | February 2, 2022

Newbridge Financial Services Group, Inc. Buys Apple Inc, NVIDIA Corp, NXP Semiconductors NV, ...

Investment company Newbridge Financial Services Group, Inc. (Current Portfolio) buys Apple Inc, NVIDIA Corp, NXP Semiconductors NV, Microsoft Corp, Tesla Inc, sells NIO Inc, Lemonade Inc, Alibaba Group Holding, Carnival Corp, Blackstone Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Newbridge Financial Services Group, Inc..

Yahoo | January 19, 2022

Jefferies Thinks Heron Therapeutics’ Stock is Going to Recover

Jefferies analyst Kelly Shi maintained a Buy rating on Heron Therapeutics (HRTX – Research Report) today and set a price target of $23.00. The company's shares closed last Friday at $8.70, close to its 52-week low of $8.09. According to TipRanks.com, Shi 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -19.9% and a 17.9% success rate. Shi covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Legend Biotech, and ImmunoGen. Currently, the analyst consensus on Heron Therapeutics is a Strong Buy with an average price target of $35.67.

Howard Kim on TipRanks | January 18, 2022

Private Asset Management Inc Buys ASML Holding NV, Public Storage, Palantir Technologies Inc, ...

San Diego, CA, based Investment company Private Asset Management Inc (Current Portfolio) buys ASML Holding NV, Public Storage, Palantir Technologies Inc, Kimco Realty Corp, Vanguard Dividend Appreciation FTF, sells Alibaba Group Holding, Heron Therapeutics Inc, The Energy Select Sector SPDR Fund, Danaher Corp, Dominion Energy Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Private Asset Management Inc.

Yahoo | January 4, 2022

Heron Therapeutics (HRTX) Gets a Buy Rating from Needham

In a report released today, Serge Belanger from Needham maintained a Buy rating on Heron Therapeutics (HRTX – Research Report), with a price target of $24.00. The company's shares closed last Thursday at $9.55, close to its 52-week low of $8.29. According to TipRanks.com, Belanger is a 2-star analyst with an average return of 1.0% and a 39.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Heron Therapeutics with a $42.00 average price target.

Catie Powers on TipRanks | December 9, 2021

Why Heron Therapeutics Shares Rose Nearly 15% This Week

The company announced on Thursday that its drug Zynrelef (bupivacaine and meloxicam) has been given Food and Drug Administration supplemental New Drug Application approval for more uses. The drug, the first FDA-approved dual-acting anesthetic, had already been approved in May for post-surgical pain relief after the removal of bunions, open inguinal hernia operations, or total knee replacement in adults. It has shown to be more effective than just bupivacaine alone, the current standard of care for post-surgical pain, and it gives surgeons a non-opioid solution for post-surgical pain, reducing the possibility of addiction.

Yahoo | December 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5403 seconds.